ADAR1 Capital Management, LLC, a 10%+ owner of Tenax Therapeutics, Inc. (TENX), disclosed another open-market purchase of the small-cap biopharmaceutical company’s stock in a Form 4 filed with the SEC. On August 24, 2026, the investment firm bought 107,374 shares at $1.75 apiece, an outlay of $188,355.47 paid from its own funds rather than acquired through options or other compensation.
Following the purchase, ADAR1’s indirect holdings in Tenax Therapeutics stand at 4,853,818 shares, held through an entity structure rather than in the manager’s own name — a common arrangement for institutional and fund-affiliated insiders.
Part of a Broader Buying Pattern
This single transaction is not an isolated event. It is the latest in a string of three open-market purchases by ADAR1 Capital Management between August 20 and August 24, 2026. Taken together, those three purchases total $1,814,147 in Tenax Therapeutics stock acquired in under a week. Our system flags this kind of repeated, closely timed buying activity from the same insider as a ‘cluster buy’ — a signal category distinct from a single, one-off purchase.
Cluster buys tend to draw more attention than isolated insider transactions because they show sustained conviction over multiple trading days rather than a single decision point. When the same insider returns to the market repeatedly to add shares at varying prices over a short window, it suggests the purchases weren’t a one-time reaction to a specific price dip but part of a deliberate accumulation strategy.
Why This Kind of Filing Gets Noticed
Academic research on insider trading has found that clustered buying — multiple insiders, or the same insider multiple times, purchasing shares in a short period — has historically correlated with periods of subsequent outperformance relative to the broader market, on average and across large samples of filings. That said, this is a statistical pattern observed in aggregate data, not a guarantee tied to any individual filing, and it says nothing about what happens next for Tenax Therapeutics specifically.
Form 4 filings like this one are mandatory disclosures required whenever an officer, director, or 10%+ owner buys or sells company stock, and they are made public shortly after the transaction occurs. ADAR1 Capital Management’s status as a 10%+ owner means its trading activity is closely watched by other market participants who track Tenax Therapeutics, given the size of its stake and its now-demonstrated pattern of adding to that position across multiple August sessions.
→ See all TENX coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.